NEW YORK, April 10, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc. ("Synergy" or the "Company") (NASDAQ:SGYP) and certain of its officers, on behalf of shareholders who purchased Synergy securities during the period between September 5, 2017 and November 14, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sgyp.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On September 5, 2017, Synergy revealed that it had closed on a "non-dilutive" $300 million loan from CRG Partners III L.P., which would be available to the Company "when needed" to fund its operations through 2019. On November 14, 2017, Synergy divulged the loan agreement terms, that was not previously disclosed, prevented the Company from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash, and therefore, Synergy was conducting a secondary offering of its shares. Consequently, contrary to Defendants' previous statements at the beginning of the Class Period, the loan was not available to Synergy "when needed," would result in dilution of the outstanding shares, and would not be sufficient to fund operations through 2019, without dilution. Following the news, Synergy stock dropped as low as $1.68 per share.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sgyp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Same sparkle, different story: how lab-grown diamonds are transforming the market
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Capital One Says AML Review Led to Closure of Trump Organization Accounts 



